# Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

> **NCT00162097** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 21 (actual)

## Conditions studied

- HIV Infections
- Hepatic Impairment

## Interventions

- **DRUG:** efavirenz containing antiretroviral regimen
- **DRUG:** efavirenz containing antiretroviral regimen
- **DRUG:** efavirenz containing antiretroviral regimen
- **DRUG:** efavirenz containing antiretroviral regimen

## Key facts

- **NCT ID:** NCT00162097
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2010-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162097, "Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00162097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*